Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP02 in Metastatic Pancreatic Cancer
NCT00813163Phase 2Completed
- Sponsor
- PharmaEngine, Inc.
- Start
- Jan 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in pancreatic cancer (PC), sponsored by PharmaEngine, Inc. Primary endpoint: 3-Month Survival Rate. Started Jan 2009; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00813163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813163.